Removal of the bladder, called radical cystectomy, is the preferred treatment for patients with muscle-invasive bladder cancer (MIBC) as well as for some with non-muscle-invasive bladder cancer (NMIBC ...
Gross hematuria in a younger adult prompted rapid urologic evaluation, underscoring that bladder cancer can present before ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
ImmunityBio’s findings showed that ANKTIVA plus BCG generated savings of up to $151,438 per cystectomy avoided over a ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis. The optimal duration of antibiotic prophylaxis is still unknown.
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results